An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab

Part of paid clinical trials in Chicago, Illinois.

Sponsor
Bristol-Myers Squibb
Study ID
NCT02754141
Phase
PHASE1/PHASE2
Status
Completed

Conditions

  • Malignant Solid Tumor

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • BMS-986179 — BIOLOGICAL
    Specified dose on specified days
  • Nivolumab — BIOLOGICAL
    Specified dose on specified days
  • rHuPH20 — BIOLOGICAL
    Specified dose on specified days

Study Details

The purpose of this study is to assess the safety and tumor-shrinking ability of experimental medication BMS-986179 alone and when combined with Nivolumab, in patients with solid cancers that are advanced or have spread.

Key Dates

Start date
Jun 21, 2016
Status verified
Mar 2023
Primary completion
Oct 12, 2021
Completion
Oct 12, 2021

Study Design

Enrollment
235 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Arm A-Monotherapy
    BMS-986179, dose as specified
  • Experimental: Arm B- Combination Therapy
    BMS-986179 + nivolumab, dose as specified
  • Experimental: Arm C-Combination Therapy
    BMS-986179 + rHuPH20, dose as specified

Primary Outcome Measure

Number of Participants With Drug Related AEs, SAEs, AEs Leading to Discontinuation and Deaths. [ Time Frame: From first dose to 100 days post last dose: Part 1 up to 25.1 months, Part 2 SC up to 17.5 months, RCC Mono up to 28.1 months, Part 2 up to 27.2 months. ]

Locations (8)

FacilityCityStateZIPSite coordinators
Local Institution - 0028ChicagoIllinois60611-
Local Institution - 0001BaltimoreMaryland21287-
Local Institution - 0022BostonMassachusetts02215-
Local Institution - 0023BuffaloNew York14263-
Local Institution - 0005New YorkNew York10032-
Local Institution - 0020PittsburghPennsylvania15232-
Local Institution - 0004NashvilleTennessee37203-
Local Institution - 0009DallasTexas75230-

Find similar trials in Chicago, IL

By research site
Local Institution - 0028· Chicago, ILLocal Institution - 0001· Baltimore, MDLocal Institution - 0022· Boston, MALocal Institution - 0023· Buffalo, NYLocal Institution - 0005· New York, NYLocal Institution - 0020· Pittsburgh, PA

Related Studies